Pfizer says it removed some conditions from its Metsera bid

Core Viewpoint - Pfizer is adjusting its bid for Metsera by removing certain conditions to counter Novo Nordisk's competing $10 billion offer for the obesity drug developer [1] Group 1 - Pfizer's revised bid aims to strengthen its position against Novo Nordisk's substantial offer [1] - The competitive landscape for obesity drug developers is intensifying, highlighting the strategic importance of Metsera in the market [1] - The move reflects Pfizer's commitment to expanding its portfolio in the obesity treatment sector [1]